NASH Observatory

⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.

Lung transplantation recipients with NAFLD

Advanced hepatic fibrosis and cirrhosis are absolute contraindications to lung transplantation. In a retrospective analysis of 150 transplanted patients, A. J. Trindade et al. (Brigham and Women’s Hospital/Harvard Medical School, and Vanderbilt University Medical Center, USA) aimed to determine if mild-moderate NAFLD contributes to increased adverse outcomes...
Read MoreLung transplantation recipients with NAFLD

Defining comprehensive models of care for NAFLD Liver health specialists

Prof. Jeffrey V Lazarus

NAFLD places a substantial burden on healthcare systems and receives little attention from public health authorities. Ambitious measures are needed to improve preparedness globally. Prof Lazarus, Spain, discusses how to establish care pathways tailored to meet patients needs but also that optimally use existing resources. Modifiable risks factors are particularly important in a comprehensive strategy.

Read MoreDefining comprehensive models of care for NAFLD Liver health specialists

Treatment of 3 major risk factors and fibrosis stage regression

Currently, no established hierarchy exists for the influence of metabolic risk factors on NAFLD progression. In this retrospective cohort study, V. J. H Yao et al. (CUNY School of Medicine/Sophie Davis Biomedical Education Program, New York, USA) investigated and ranked the independent and combined effects of three major risk...
Read MoreTreatment of 3 major risk factors and fibrosis stage regression

Japan: NAFLD may affect half of the population by 2040

In this systematic review and meta-analytic approach combining study level with individual patient-level data, T. Ito et al. (Nagoya University Graduate School of Medicine, Japan) aimed to investigate the epidemiology of NAFLD in Japan with a focus on lean NAFLD. The overall NAFLD prevalence was 25.5%, and increased over time...
Read MoreJapan: NAFLD may affect half of the population by 2040

Dynamic changes in liver macrophage subsets during NASH

Macrophage-mediated inflammation is critical in the pathogenesis of NASH. However, the underlying mechanisms remain unclear. In this study, S. Daemen et al. (Washington University School of Medicine, St. Louis, MI, USA) evaluated intra-hepatic macrophage composition in a mouse model of obesity with NAFLD and in a model of NASH...
Read MoreDynamic changes in liver macrophage subsets during NASH

MAFLD or NAFLD: reasons and relevance of a single-letter change

Recently, a consensus recommended 'metabolic (dysfunction) associated fatty liver disease' as a more appropriate name to describe fatty liver disease associated with metabolic dysfunction (MAFLD). This single-letter change in the NAFLD acronym suggests that the old acronyms should be abandoned...

Read MoreMAFLD or NAFLD: reasons and relevance of a single-letter change

Liver transplantation indications in Saudi Arabia: NASH has eclipsed HCV

Our understanding of fatty liver syndromes and their relationship with the metabolic syndrome has improved over recent decades and, paralleling this, we are now at the dawn of the NAFLD (non-alcoholic fatty liver disease) to MAFLD (metabolic-associated fatty liver disease) transition...
Read MoreLiver transplantation indications in Saudi Arabia: NASH has eclipsed HCV

Prevalence of NAFLD and MAFLD in the US population

S. Ciardullo et G. Perseghin (Policlinico di Monza, and University of Milano Bicocca, Italy) performed a cross-sectional study of adults recruited in the 2017-2018 NHANES Survey, a representative sample of the general US population, in order to determine the prevalence of NAFLD, MAFLD and associated advanced fibrosis in the US population...
Read MorePrevalence of NAFLD and MAFLD in the US population